Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13014975 | 0.91 | MAPT (0.43) | SMN1; SMN2L3MBTL1LMNACYP1A2ALDH1A1 | |
| SCHEMBL14008579 | 0.91 | MAPT (0.41) | SMN1; SMN2L3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL13014964 | 0.91 | TDP1 (0.44) | SMN1; SMN2L3MBTL1LMNACYP1A2CYP2D6 | |
| SCHEMBL18936896 | 0.88 | ALDH1A1 (0.47) | KDM4ESMN1; SMN2LMNAALDH1A1ATM | |
| SCHEMBL14008575 | 0.87 | ALDH1A1 (0.42) | SMN1; SMN2L3MBTL1CYP1A2ALDH1A1ATM | |
| SCHEMBL2298369 | 0.83 | TDP1 (0.45) | KDM4ESMN1; SMN2L3MBTL1LMNACYP1A2 | |
| SCHEMBL20703549 | 0.82 | TDP1 (0.42) | SMN1; SMN2L3MBTL1CYP1A2ALDH1A1ATM | |
| SCHEMBL13014980 | 0.82 | AKR1C3 (0.42) | KDM4ESMN1; SMN2L3MBTL1LMNAALDH1A1 | |
| SCHEMBL5676255 | 0.82 | TDP1 (0.44) | SMN1; SMN2L3MBTL1LMNACYP1A2ALDH1A1 | |
| SCHEMBL3223924 | 0.82 | TDP1 (0.44) | KDM4ESMN1; SMN2L3MBTL1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | disclosed |
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| CN-106243037-A | The substituted phenylurea of part and phenyl amide as Rhizoma et radix valerianae compounds receptor | 格吕伦塔尔有限公司 | 2016-12-21 | — | — | CN | disclosed |
| US-9120756-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120756-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120756-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| WO-2010127856-A1 | SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127856-A1 | SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
| EP-2150531-A2 | NOVEL VANILLOID RECEPTOR LIGANDS, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008125295-A2 | NOVEL VANILLOID RECEPTOR LIGANDS, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125295-A2 | NOVEL VANILLOID RECEPTOR LIGANDS, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | TRPV1, TRPV2, TRPV3 | KDM4E 4337/4885SMN1; SMN2 3552/4885L3MBTL1 4855/4885 |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | KDM4E 2616/4885SMN1; SMN2 3477/4885L3MBTL1 4707/4885 |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | KDM4E 2471/4885SMN1; SMN2 3176/4885L3MBTL1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.